Patients undergoing bone marrow transplantation are profoundly immunosuppressed as a result of their intensive myeloablative chemotherapy and are at high risk for opportunistic fungal infections mainly caused by Candida spp and Aspergillus spp. Trichosporon beigelii (T beigelii) has emerged as a life-threatening opportunistic pathogen in granulocytopenic and immunocompromised hosts and there is a marked increase in cases reported in the literature. Response to antifungal agents is poor, mortality is high and immunological recovery is the most important factor for a favorable outcome in patients with trichosporonosis. We present three cases of T. beigelii infection in patients undergoing allogeneic bone marrow transplantation in our center and we review cases described in the literature. Bone Marrow Transplantation (2000) 25, 745-749. Keywords: tricosporon beigelii; bone marrow transplantation; immunosuppression Trichosporon beigelii (T. beigelii) is a ubiquitous yeast which inhabits the soil, but may also be present in the human skin and respiratory tract as normal flora.
Trichosporon beigelii (T. beigelii) is a ubiquitous yeast which inhabits the soil, but may also be present in the human skin and respiratory tract as normal flora. 1 It is known to cause white piedra, an innocuous, superficial hair infection commonly found in tropical and subtropical regions; 2 the yeast occasionally produces superficial dermatologic infections in an immunocompetent host, but can cause fatal systemic mycosis in immunocompromised patients. Populations at risk are people with HIV infection, bone marrow and organ transplant recipients, patients with profound neutropenia, low birth weight and premature infants 3 and patients with foreign bodies (ie prosthetic heart valves or indwelling catheters). 4, 5 In the literature rare cases of cysto-peritoneal shunt infection, peritonitis, chronic meningitis, stenosing esophagitis, endophthalmitis, arthritis, cholangitis and hepatitis caused by T. beigelii have been reported. [6] [7] [8] [9] [10] [11] [12] [13] Two antigenic types (T. ashaii, T. mucoides) have been demonstrated to be the causative agents of summer-type hypersensitivity pneumonitis first described in Japan. 14 The susceptibility of T. beigelii to antifungal agents is conflicting in various reports and its in vitro sensitivities may not correlate with in vivo antifungal efficacy. 15, 16 The infection is usually insidious and the diagnosis is difficult to make because of its close resemblance to Candida species in both clinical features and histopathologic findings. 17 Little is known of host defence mechanisms against this yeast besides that the number of neurophils at the early stage of infection of other host defence mechanisms such as TNF-alfa overproduction in the lung have been demonstrated to be important in the prognosis of trichosporonosis in a murine model study. 18 The results reported in the literature with disseminated T. beigelii infection in immunocompromised hosts are disappointing; the majority of patients have died despite antifungal therapy and a successful outcome after infection appears to be related primarily to the patient's immunological recovery.
Patients and methods

Case 1
A 17-year-old boy received an allogeneic BMT from his HLA-identical brother for ␤ thalassemia major in February 1997. The patient was prepared for transplant with BU 14 mg/kg + CY 200 mg/kg and CsA alone as GVHD prophylaxis. 19 He received 1.37 × 10 8 /kg of unmanipulated nucleated cells. Absolute neutrophil count Ͼ500/mm 3 and platelet recovery (Ͼ20 000/mm 3 ) were achieved on days +15 and +12 respectively, and allogeneic engraftment was documented on day +21 by globin chain synthesis. 19 He started antifungal prophylaxis with conventional amphotericin B (0.3 mg/kg) from day +8 of the conditioning protocol. On day +20 he became febrile and Pseudomonas aeruginosa was isolated from blood cultures obtained during febrile episodes. On day +27 he showed a transient neutropenia associated with a persistent thrombocytopenia. The post-BMT course was complicated by iatrogenic diabetes which necessitated regular subcutaneous insulin therapy. The patient was discharged well on day +35. He had four other admissions to hospital; the second for seizures due to CsA neurotoxicity, the third for hypoglycemia, the fourth for fever and anaemia and most recently he was admitted on day +95 for fever and appearance of necrotic lesions on the lower limbs consistent with disseminated T. beigelli infection. The fungus grew from multiple blood cultures, and from cultures from the necrotic lesions.
Immunosuppressive therapy with CsA and prednisolone was stopped and antifungal therapy with amphotericin B commenced. Susceptibility to antifungal agents showed complete resistance to 5 flucytosine in all and to amphotericin B in one isolate. Despite this isolated documentation of resistance, antifungal therapy with amphotericin B was continued after his discharge (+161). For 4 weeks 5 flucytosine was given with amphotericin B. Two bronchoalveolar lavages (BAL) (at 1 month intervals) had also been performed and both of them were negative for T. beigelii. During hospitalization antiviral therapy with gancyclovir was given for CMV pp65-antigenemia without signs of CMV disease. During antifungal therapy the patient developed sinus tenderness, but CT scanning of brainorbits-sinus was negative for focal lesions. The necrotic lesions on the limbs became small abscesses in time, and two of them increased in size. Ultrasonographic examination showed walled collection consistent with haematoma or pus. After 2 months of continuous antifungal therapy he became afebrile, the necrotic lesions improved gradually and resolved completely and blood cultures became negative. On day +161 he was transferred to his own town where he was admitted several times to hospital for reactivation of chronic GVHD (gut involvement) and recurrence of fungemia. In March 1998 he returned to the day hospital with cardiac insufficiency and pneumonia. Endocarditis involving his heart valves was diagnosed on echocardiogram which revealed a massive vegetation on the mitral and aortic valves; unfortunately, surgery was not possible because of his poor clinical condition. He continued with antifungal agents and died of disseminated trichosporonosis 14 months after BMT.
Case 2
An 8-year-old Russian girl underwent an allogeneic CD34 + selected peripheral blood stem cell (PBSC) transplant from her HLA-haploidentical mother for T-ALL in first relapse, in September 1997. The conditioning regimen included BU 16 mg/kg and CY 200 mg/kg, GVHD prophylaxis was with CsA and short-course methotrexate (up to day +6). Peripheral mononuclear cells were collected by apheresis on 2 consecutive days using the CS3000 cell separator (Baxter, Fenwall, IL, USA). Leukapheresis products were positively selected for CD34
+ cells with the Ceprate System (CellPro, Bothell, WA, USA) and cryopreserved. A total number of 4.27 × 10 6 CD34 + cells/kg body weight were infused 14 days after the last collection. The patient had a rapid leukocyte and platelet recovery (ANC Ͼ500/mm 3 and platelets Ͼ20 000/mm 3 on days +15 and +16, respectively). On day +20 she suffered a sharp drop in platelets and granulocytes and a bone marrow biopsy carried out on day +21 showed severe cytopenia. As analysis of engraftment by VNTR-PCR confirmed 50-60% donor hemopoiesis on bone marrow, unmanipulated marrow cells from the same donor (nucleated cells infused 4.06 × 10 8 /kg body weight) were infused on day +28, but no evidence of hematological recovery ensued. On day +44 following 3 days of anti-lymphocyte globulin, the patient received cryopreserved PBSC (one bag unprocessed and another processed by CELL-PRO) and a total of 15.62 × 10 6 CD34 + cells/kg body weight were infused. She remained aplastic and became febrile. Several gram-negative and -positive bacteria were isolated from blood cultures (Staphylococcus epidermidis, Staphylococcus saccarolyticus, Acinetobacter baumanii, Pseudomonas aeruginosa). T. beigelii grew from blood cultures on days +76 and +81 although the patient had received prophylaxis with amphotericin B from day +8 at a dose of 0.5 mg/kg. The fungus was resistant to 5-flucytosine; therefore fluconazole 400 mg/daily was started even though it had not been sensitivity tested. On day +50 she developed stomatitis which progressed into necrotic lesions involving the palate and lips; similar necrotic lesions developed on both thumbs. Cultures taken from these sites were positive for Staphylococcus epidermis and negative for T. beigelii. A biopsy from the necrotic lesions was not performed. The patient remained severely aplastic, developed bacterial and fungal sepsis despite administration of hemapoietic growth factors and combined antibiotic and antifungal therapy and died 93 days after the first PBSC infusion.
Case 3
An 18-year-old boy was transplanted for ␤ thalassemia major from his HLA-phenotypically identical mother in November 1997. He was conditioned with BU 14 mg/kg and CY 200 mg/kg. He received CsA and short-course methotrexate (up to day +6) for prevention of GVHD. Engraftment occurred promptly with neutrophil recovery to Ͼ0.5 × 10 9 /l and platelet count Ͼ20 × 10 9 /l achieved on days +15 and +18, respectively. Beta chain synthesis and cytogenetic analysis of bone marrow performed on day +22 confirmed complete donor engraftment. He started antifungal prophylaxis with conventional amphotericin B (0.3 mg/kg) on day +8 according to the conditioning protocol, and on day +10 therapy was switched to liposomal amphotericin B at a dose of 1 mg/kg. He became febrile from day +7, on day +12 he developed grade II skin acute GVHD and immunosuppressive therapy with methylprednisolone was started. GVHD progressed and he developed grade IV acute GVHD (skin and gut involvement) which necessitated more aggressive treatment with high-dose methylprednisolone (10 mg/kg) together with monoclonal antibody anti-CD3 (Orthoclone OKT3 Ortho Pharmaceutical, New Jersey, USA) at a dose of 5 mg/day for 12 consecutive days. Complete resolution of severe aGVHD occurred on day +40. Reactivation of skin GVHD occurred on day +55 and resolved with methylprednisolone at a dose of 5 mg/kg. He had a second febrile episode on day +19, lasting for 3 consecutive days. T. beigelii grew in three blood cultures performed on days +16, +20 and +21; antifungal susceptibility tests showed complete resistance to 5-flucytosine and susceptibility to fluconazole was not assessed. Antifungal therapy was changed from liposomal amphotericin B to amphotericin B colloidal dispersion at a dose of 5 mg/kg and fluconazole (400 mg/day) was added to therapy for 4 weeks. He received liposomal amphotericin B until discharge (+78). He also had positive blood cultures for Staphylococcus epidermidis with no clinical signs and only one positive culture from gastric contents for Candida albicans on day +21. The central venous catheter (CVC) was removed on day +47 and a new one inserted at the same site; culture from the tip was negative. The patient did not show any clinical sign of bacterial and/or fungal sepsis and was discharged fit 78 days after BMT with optimal hematological recovery and free of his congenital disease. He is currently undergoing post-BMT follow-up in his own town with no signs of infection or hematological problems.
Susceptibility tests
Susceptibility tests of T. beigelii isolates to various antifungal agents were performed by agar diffusion assay. MICs were not performed.
Discussion
Invasive fungal infections remain one of the major causes of morbidity and mortality in immunocompromised hosts including bone marrow and organ transplant recipients. 20, 21 The institution of antifungal prophylaxis with potent antifungal agents has reduced the incidence of mortality due to invasive fungal infections after BMT, [20] [21] [22] [23] [24] but over the past decade infections with rare and new fungal opportunists have become a significant problem in treatment of immunocompromised hosts. 25 This is probably due to multiple factors including use of invasive surgical procedures and prosthetic materials (ie prosthetic heart valves, central venous catheters) or of intensive chemotherapy that induce severe immunosuppression; also, the expanding group of organ and marrow recipients and persons with HIV infection has contributed to the increase in patients at risk for opportunistic infections. As a result, many ubiquitous fungi that previously simply colonized skin and gastrointestinal tract have now become potential invasive and life-threatening pathogens. T. beigelii is one of these fungal agents. The first case of T. beigelii infection was reported in 1970. 26 Over the past decade disseminated disease due to the yeast T. beigelii has been increasingly documented in severely immunosuppressed patients. Portals of entry into deep tissues are usually respiratory or gastrointestinal tract and skin. 2 The fungus can cause invasive disease at a single organ site or in a disseminated form in which lungs, kidneys, skin and eyes are the main targets. T. beigelii can cause fungemia even in immunocompetent individuals. In these cases, the infection is related either to the presence of a foreign body such as a prosthetic heart valve, an indwelling catheter or to intravenous drug abuse. 4 All three cases reported here were profoundly immunosuppressed and neutropenic at the time they developed infection with T. beigelii. The patient reported in case 1 suffered from delayed bone marrow recovery and could not eliminate the organism. Despite prolonged antifungal therapy he developed a severe complication of fungal infection. Endocarditis caused by T. beigelii that involves native or prosthetic heart valves has been reported and despite aggressive medical and surgical therapy the prognosis is poor. 4, 27, 28 The surgical approach includes valve replacement which helps to eradicate the colonization but is not sufficient to cure the infection, and the mortality rate of these patients is high. 4 Unfortunately, the patient described
Bone Marrow Transplantation here could not undergo open heart surgery because of his poor clinical condition and died of disseminated trichosporonosis 14 months after BMT. The second patient died of polymicrobial infection after prolonged marrow aplasia; the necrotic lesions were not biopsied and negative skin cultures do not exclude fungal invasion of affected sites. She probably developed fungal sepsis concomitant with bacterial; organ involvement was not assessed due to her poor clinical condition, so the exact contribution of T. beigelii infection to the patient's death is difficult to estimate. Only one patient who had multiple positive blood cultures in the absence of clinical manifestations of systemic infection resolved the colonization. This patient had optimal and rapid trilineage marrow recovery and eliminated the fungus after treatment with amphotericin B and fluconazole. Few cases with normal neutrophil counts who recovered from infection without antifungal therapy have been reported in the literature. 2 One of the general concepts for combating yeast infections is to remove any foreign body such as an indwelling catheter or prosthetic heart valve. Two patients (cases 1 and 3) underwent removal of the CVC after documentation of a fungal infection. Cultures from the tip of the CVCs were negative and the patient with delayed marrow recovery could not eliminate the fungus while the other one cleared the colonization. We believe that in this case the rapid immune reconstitution was the major determinant of fungemia resolution.
A false positive latex agglutination test for Cryptococcus neoformans in the serum may occur as a cell wall antigen of yeast cross-reacts with the capsular polysaccaride of C. neoformans. [29] [30] [31] All three patients described here were monitored weekly for antigenemia for Aspergillus, Candida and Cryptococcus with a latex agglutination assay as a part of routine post-BMT surveillance. Only case 2 had two positive Cryptococcal latex agglutination tests along with positive blood cultures for T. beigelii, while in the other two patients the tests were persistently negative.
Diagnosis relies on clinical suspicion with microbiological confirmation. There have been conflicting results in the literature regarding susceptibilities of this organism to various antifungal agents. Furthermore, the efficacy of antifungal drugs does not always correlate with susceptibility in vitro. Clinical isolates of T. beigelii are generally reported to be susceptible to amphotericin B, but sensitivities to antifungal agents can also vary depending on the methodology used. 4, 27, 32 Rarely, T. beigelii may be resistant to amphotericin B in vitro 16 and flucytosine also is variably active. 4 There are data suggesting that certain azoles (including miconazole, fluconazole and itraconazole) are active against most T. beigelii isolates and should be considered as possible alternative therapeutic agents. 4, 16, 33 The T. beigelii isolates from our patients were sensitive to azoles (miconazole, econazole, ketaconazole, clotrimazole). Susceptibility to fluconazole, used in cases 2 and 3, was not assessed. More recently, a new triazole derivative, voriconazole (UK-109,496) has been reported to have potent in vitro antifungal activity against yeasts, moulds and filamentous fungi. [34] [35] [36] [37] Although its clinical effectiveness is still to be established, this newer triazole appears to be promising in the treatment of human mycoses.
At present, therapy is not efficacious in all cases of T. beigelii and immunological recovery of patient seems to be essential in the resolution of the infection, as confirmed in this report. Clinical suspicion is essential for earlier institution of antifungal therapy which can decrease the high mortality rate and improve outcome for patients with disseminated trichosporonosis.
